CRSP Stock Is On A Wild Ride After Sickle Cell Treatment Approval. These Diseases Could Be Next.
Update: 2023-12-11
Description
Biotech stocks could be at a major turning point after FDA approval of the first gene editing drug using CRISPR technology to treat sickle cell disease.
Government approval of these groundbreaking treatments could generate an unprecedented wave of medical innovation. But gene editing therapies aren't without risk, and questions remain about the safety and cost effectiveness of these experimental treatments.
On this episode of Growth Stories, we dive into the science of gene editing treatments and how the boom in gene therapy drug approvals could transform the healthcare industry.
Learn more about your ad choices. Visit megaphone.fm/adchoices
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
1.0x
